Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate

NCT01358968 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01358968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01358968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
December 31, 2012
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer